Serina Therapeutics (SER) Stock Price, News & Analysis
Company Description
Serina Therapeutics (NYSE: SER) is classified in the biotechnology industry within the Pharmaceutical Preparations sector and carries a market capitalization of $42.3M, ranking #5,914 among all listed U.S. companies by market cap.
SER has declined 49.1% over the past year. Shares last traded at $2.80.
For FY2025, Serina Therapeutics reported revenue of $130K with net income of -$19.2M and diluted earnings per share of -$1.91. The company operates at a net profit margin of -14755.4%.
This page collects what Stock Titan holds for SER, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Serina Therapeutics (SER) stock last closed at $2.80. Over the past 12 months, the stock has lost 49.1%. At a market capitalization of $42.3M, SER is classified as a micro-cap stock with approximately 15.0M shares outstanding.
SER Rankings
Latest News
Serina Therapeutics has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 2 articles coincided with positive price movement and 8 with negative movement. Key topics include earnings, management. View all SER news →
SEC Filings
Serina Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 3, 1 Form 4, 1 Form 10-Q. The most recent filing was submitted on August 13, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SER SEC filings →
Insider Radar
Insider buying activity at Serina Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Serina Therapeutics generated $130K in revenue in FY2025, operating income reached -$24.0M (-18478.5% operating margin), and net income was -$19.2M, reflecting a -14755.4% net profit margin. Diluted earnings per share stood at -$1.91. The company generated -$18.0M in operating cash flow. With a current ratio of 1.71, the balance sheet reflects a strong liquidity position.
Upcoming Events
SAD TFL data release
Topline SAD results
Top-line data readout
Listing compliance cure deadline
Deadline to regain NYSE compliance
Serina Therapeutics has 5 upcoming scheduled events. The next event, "SAD TFL data release", is scheduled for January 1, 2027 (in 137 days). Investors can track these dates to stay informed about potential catalysts that may affect the SER stock price.
Short Interest History
Short interest in Serina Therapeutics (SER) currently stands at 284.5 thousand shares, down 0.3% from the previous reporting period, representing 13.5% of the float. Since August 2025, short interest has increased by 32.5%. This moderate level of short interest indicates notable bearish positioning. The 5.2 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Serina Therapeutics (SER) currently stands at 5.2 days, up 51.2% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 423% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 5.2 days.
SER Company Profile & Sector Positioning
Serina Therapeutics (SER) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NYSE.
Investors comparing SER often look at related companies in the same sector, including Vtv Therapeutics (VTVT), Polypid Ltd. (PYPD), JUPITER NEUROSCIENCES, INC. (JUNS), Relmada Therapeutics Inc (RLMD), and MAIA Biotechnology Inc. (MAIA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SER's relative position within its industry.